<?xml version="1.0" encoding="UTF-8"?>
<ref id="B197">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Revuelta-Herrero</surname>
    <given-names>J. L.</given-names>
   </name>
   <name>
    <surname>Chamorro-de-Vega</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Rodríguez-González</surname>
    <given-names>C. G.</given-names>
   </name>
   <name>
    <surname>Alonso</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Herranz-Alonso</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Sanjurjo-Sáez</surname>
    <given-names>M.</given-names>
   </name>
  </person-group> (
  <year>2018</year>). 
  <article-title>Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients</article-title>. 
  <source>Ann. Pharmacother.</source>
  <volume>52</volume> (
  <issue>1</issue>), 
  <fpage>11</fpage>–
  <lpage>18</lpage>. 
  <pub-id pub-id-type="doi">10.1177/1060028017728294</pub-id>
  <pub-id pub-id-type="pmid">28836468</pub-id>
 </mixed-citation>
</ref>
